Hechos Relevantes

About the non-monetary capital increase

Relevant information about the non-monetary capital increase that lets Inveready Innvierte Biotech II access to Bionaturis shareholders

For the official disclosing, please, click here (only in Spanish)

August 8th, 2016|Hechos Relevantes|Comments Off|

Change in the liquidity provider

For the official disclosing, please, click here (only in Spanish)

August 1st, 2016|Hechos Relevantes|Comments Off|

Significant Shares June 30th, 2016

D. Víctor Manuel Infante Viñolo (directly and indirectly): 39,28 %

For the official disclosing, please click here (only in Spanish)

July 7th, 2016|Hechos Relevantes|Comments Off|

Ordinary General Shareholders Meeting Agreements (Only in Spanish)

For the official disclosing, please, click here

July 1st, 2016|Hechos Relevantes|Comments Off|

Approval of adaptation of the internal code of conduct (only in Spanish)

For the official disclosing, please click here

June 3rd, 2016|Hechos Relevantes|Comments Off|

Bionaturis Group growth, in the MedCap Forum

Bionaturis Group takes part one more year in the Small and Medium-Size Companies Forum -MedCap-, on May 31st and June 1st in Madrid.

Bionaturis Group CEO, Victor Infante, is the person in charge of presenting the latest milestones achieved by the company, among with we can highlight the establishment of the subsidiary BNT China Biosciences in China, the signing of a contract with the US National Institute of Environmental Health (NIEHS) and the recent acquisition of the company ZIP Solutions, that has signed a co-development and exclusive license agreement with a leading multinational company for the final development and market of Splittera® technology.

Thanks to these latest operations, Bionaturis Group continues positioning as a reference company in its area, through its four companies and two subsidiaries with presence in Europe, USA and Asia. The Group offers premium services and products for human and animal health.

In this edition of the MedCap Forum, Bionaturis Group takes part in both ‘One to One’ meetings and the Discovery Meeting, with a lecturer in the afternoon on May, 31st, available here.

About the MedCap

The 11nd MEDCAP Forum gathers the main Small and Medium Size Companies listed on the Spanish Stock Exchange Market as well as institutional investors, brokers and financial analysts. The program includes both sectorial and general round tables, as well as the possibility of holding ‘One to One’ meetings. The main goal of the event is to stimulate the liquidity and founding of these companies.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). In addition to this […]

May 31st, 2016|Blog english, congress, Hechos Relevantes|Comments Off|

Ordinary General Shareholders’ Meeting

Bionaturis announces the Ordinary General Shareholders’ Meeting to be held on 30 June 2016 at 12:30 p.m.

For the official disclosing, please, click here

May 30th, 2016|Hechos Relevantes|Comments Off|

Bionaturis Group increases recurring sales 21.7%, keeping a CAGR of 24.1% on net sales between 2012 and 2015

Bionaturis Group has released FY2015 audited results showing a continuous growth in many of its main performance indicators at organic level. Thus, the recurring business coming from the CRO and consumer products divisions has grown 21.7% YOY, meaning a CAGR of 24.1% on net sales for the whole group between 2012-15. Regarding the human and animal health division -which business model requires a more focused analysis on the richness and quality of the pipeline- the Group announced the addition of up to six new programs, five of which are targeted specifically to highly lucrative niche markets within animal health, positioning the group as a partner of choice for cutting-edge developments in this sector.

From the angle of an effective presence in other international markets the Group signed an outstanding agreement with the Administrative Committee of the high technology Industrial development zone of Changshu City (Jiangsu, China), which shall support the start up phase of the subsidiary BNT China Biosciences. Also during 2015 the subsidiary BBD Biophenix USA was created, generating an immediate effect on the increase of contracts with U.S. entities, such as the one signed with the NIH (National Institute of Health), a leading global institution in the health sector.

For further details, click here

April 30th, 2016|Blog english, Hechos Relevantes|Comments Off|

Closing of corporate transaction with Inveready

Bionaturis acquires the company Zera Intein Protein Solutions (ZIP), owned by Inveready

The acquisition is valued at 1.6 million Euros

As a result of the transaction, Inveready Biotech II fund will hold more than 5% stake of Bionaturis

For the official disclosing, please click here

April 28th, 2016|Hechos Relevantes|Comments Off|

Board of Directors Agreements: Formulation of annual figures

The Board of Directors has formulated 2015 annual figures
 -Consolidated revenue figure: 2,433 thousand Euros
-EBITDA: 48 thousand Euros
 
For the official disclosing, please, click here

April 7th, 2016|Hechos Relevantes|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR